Intravitreal Bevacizumab for Choroidal Neovascularization and Cystoid Macular Edema: A Cost-Effective Treatment?
- 1 July 2005
- journal article
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 36 (4) , 270-271
- https://doi.org/10.3928/1542-8877-20050701-03
Abstract
Ophthalmic Surgery, Lasers and Imaging Retina | In this issue of Ophthalmic Surgery, Lasers and Imaging, Rosenfeld, Moshfeghi, and Puliafito and Rosenfeld, Fung, and Puliafito describe the first patients treated with intravitreal injection of bevacizumab (Avastin; Genentech Inc., San Francisco, CA) for exudative choroidal neovascularization due to age-related macular degeneration1 and macular edema from a central retinal vein occlusion.2 TheseThis publication has 6 references indexed in Scilit:
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Macular Edema From Central Retinal Vein OcclusionOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999